Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00385671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2006
Completion date
November 30, 2009
Enrollment
407 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathy, painful